Latest Breaking News On - Society for immunotherapy of cancer annual meeting - Page 1 : comparemela.com

Theriva Biologics, Inc (NYSE:TOVX) Q4 2023 Earnings Call Transcript

Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc.

United statesSteven shallcrossTheriva biologicsManel cascalloChris calabreseVince wacherJames molloyAlliance global partnersWashington universityProduct development of theriva biologicsUniversity of pennsylvaniaAlbumin shield technologyTheriva biologics incExchange commissionSociety for immunotherapy of cancer annual meetingData monitoring committee

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

08.01.2024 - iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase 1 Study is Being Conducted in Collaboration with Ono Pharmaceutical SAN DIEGO, Jan. 08, . Seite 1

Scott wolchkoFate therapeutics incSociety for immunotherapy of cancer annual meetingOno pharmaceutical co ltdChief executive officerCancer annual meetingFate therapeutics chartAte therapeutics kursAte therapeutics aktie

FDA Grants Fast Track Designation to CAN-2409 For Pancreatic Cancer

The Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational adenovirus CAN-2409 plus prodrug Valtrex for the treatment of patients with pancreatic ductal adenocarcinoma.

Pancreatic cancer action networkNational cancer instituteDrug administrationSociety for immunotherapy of cancer annual meetingFast track designationCandel therapeuticsCancer annual meetingPaul peter takPancreatic cancer actionOpioids reduce misuse after pancreatic cancerTrack designationPancreatic cancer

Carisma Therapeutics (CARM) Announces FDA Clearance of IND Application for CT-0525

Carisma Therapeutics (CARM) Announces FDA Clearance of IND Application for CT-0525
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Steven kellyMichael klichinskySociety for immunotherapy of cancer annual meetingCarisma therapeutics incDrug administrationCarisma therapeuticsInvestigational new drugStudy may proceedChief executive officerAnnual meetingChief scientific officer

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichael klichinskySteven kellySociety for immunotherapy of cancer annual meetingExchange commissionCarisma therapeutics incCompany quarterly report on formPrnewswire carisma therapeutics incDrug administrationInvestigational new drugStudy may proceedChief executive officerAnnual meetingChief scientific officerPrivate securities litigation reform actQuarterly report